The metabolism and disposition of eltrombopag, the first-in-class small molecule human thrombopoietin receptor agonist, were studied in six healthy men after a single oral administration of a solution dose of [ 14 C]eltrombopag (75 mg, 100 Ci). Eltrombopag was well tolerated. The drug was quickly absorbed and was the predominant circulating component in plasma (accounting for 63% of the total plasma radioactivity). A mono-oxygenation metabolite (M1) and acyl glucuronides (M2) of eltrombopag were minor circulating components. The predominant route of elimination of radioactivity was fecal (58.9%). Feces contained approximately 20% of dose as glutathione-related conjugates (M5, M6, and M7) and another 20% as unchanged eltrombopag. The glutathione conjugates were probably detoxification products of a p-imine methide intermediate formed by metabolism of M1, which arises through cytochrome P450-dependent processes. Low levels of covalently bound drug-related intermediates to plasma proteins, which could result from the reaction of the imine methide or acyl glucuronide conjugates with proteins, were detected. The bound material contributes to the longer plasma elimination half-life of radioactivity. Renal elimination of conjugates of hydrazine cleavage metabolites (mostly as M3 and M4) accounted for 31% of the radiodose, with no unchanged eltrombopag detected in urine.
Introduction
Eltrombopag olamine [3-{N-[1-(3,4-dimethyl-phenyl )-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxybiphenyl-3-carboxylic acid] is an oral, nonpeptide thrombopoietin receptor agonist that has been approved for the treatment of chronic immune thrombocytopenia (ITP) (Bussel et al., 2007 (Bussel et al., , 2009 Jenkins et al., 2007; McHutchison et al., 2007) . The drug is also under investigation for treatment of thrombocytopenia associated with chemotherapy, chronic liver disease, and hematological malignancies.
Eltrombopag (Promacta; GlaxoSmithKline, 2008 ) is safe and efficacious in treating ITP. In a phase 2 study of patients with chronic ITP and platelet counts Ͻ30 ϫ 10 9 /l, 2 weeks of treatment with 50 or 75 mg of eltrombopag increased platelet counts to Ն50 ϫ 10 9 /l in more than 80% of patients (Bussel et al., 2007) . In a phase 3 study, after 6 weeks of daily treatment with 50 mg of eltrombopag, 59% of patients achieved platelet counts of Ն50 ϫ 10 9 /l (Bussel et al., 2009) . In these studies, the number of adverse events in the eltrombopag arm was comparable to that in the placebo arm, and eltrombopag was well tolerated (Bussel et al., 2007 (Bussel et al., , 2009 Jenkins et al., 2007) .
Although eltrombopag has been well tolerated in humans at therapeutic doses, there is a regulatory concern over hepatotoxicity (Promacta). Many marketed drugs have been associated with hepatotoxicity. Drug-induced hepatotoxicity ranges from mild (e.g., elevation of serum hepatic enzymes such as alanine aminotransferase) to severe (e.g., hepatic failure) (Park et al., 2005) . These events can be either intrinsic and dose-dependent or idiosyncratic and unpredictable. For eltrombopag, the hepatic effects observed in chronic, nonclinical toxicity studies in rats and dogs at maximum tolerated doses were minimal (limited to hepatocellular vacuolation at several fold the maximal clinical exposure) and reversible (CHMP assessment report for Revolade, European Public Assessment Report, 2010, http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/001110/WC500089964.pdf).
In this report, we characterized the human disposition, biotransformation, and elimination of eltrombopag using plasma, urine, and feces samples collected after a single oral administration of [ 14 C]eltrombopag olamine (solution). The potential for bioactivation of eltrombopag in humans was also evaluated. To provide perspective, results from various nonclinical studies with eltrombopag (plasma and/or liver extractability in mouse, rat, and dog) are included as supplemental data.
Materials and Methods
Chemicals and Reagents. [ 14 C]Eltrombopag olamine (bismonoethanolamine salt, specific activity of 1.378 Ci/mg, radiochemical purity of 98%) was prepared by GlaxoSmithKline (Stevenage, Hertfordshire, UK). As illustrated in Fig. 1 , a single 14 C label was located at the 3-carbon of the 1,5-dihydropyrazole moiety of the molecule. Unlabeled eltrombopag olamine (chemical purity Ͼ99%) and 2Ј-hydroxy-3Ј-amino-3-biphenylcarboxylic acid (SB-611855) , an in vitro hydrazine cleavage product of eltrombopag), were also synthesized and purified by GlaxoSmithKline (Tonbridge, Kent, UK). Chemicals and solvents of reagent or HPLC grade were purchased from standard commercial sources. Scintillation cocktails Ultima Gold, Permafluor, Ultima-Flo M, and Carbosorb CO 2 absorbent were obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA) . HPLC columns were purchased from Phenomenex (Torrance, CA).
Dosing of Human Subjects.
This open-label, single-dose study to investigate disposition of eltrombopag in healthy humans was conducted at Covance Laboratories (Madison, WI). Six healthy adult male volunteers between the ages of 30 and 55 years (body weight Ն50 kg and body mass index between 19 and 30 kg/m 2 ) were included in the study. Four subjects were white and two subjects were African American. Subjects were nonsmokers, with no history of drug or alcohol abuse and with no prescribed medication within 14 days of the study commencing. Subjects fasted at least 10 h before and 4 h after dosing. Each subject received a single oral dose of 75 mg (100 Ci) of [ the subjects, the dosing solution in each dosing bottle was analyzed before and after dose administration for any residual radioactivity in the bottle. The difference in the amount of radioactivity present in the bottle before and after dosing was the amount of [ 14 C]eltrombopag olamine ingested by the subject. Collection and Radioanalysis of Samples. Blood samples (5 ml) were drawn on the following schedule: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156 , and 168 h postdose for pharmacokinetic analysis. In addition, 40-ml blood samples were collected from each subject at predose and 4, 12, 24, and 48 h postdose for metabolic profiling. Plasma was harvested by centrifugation. Approximately half of each plasma sample collected for metabolic profiling was acidified to approximately pH 4 by addition of 3.23% phosphoric acid to stabilize any acyl glucuronides in the sample. Urine and feces were also collected from each subject predose and from 0 to 12 h and 12 to 24 h during day 1 and in 24-h intervals from 24 to 168 h postdose. One aliquot (approximately 50 ml) of each urine collection was acidified to approximately pH 4 by dropwise addition of 21.3% aqueous phosphoric acid. The fecal samples were mixed with water (3 times the sample weight) and homogenized with a probe-type homogenizer. In addition, aliquots of predose plasma, urine, and fecal homogenates were spiked with [
14 C]eltrombopag (10,000 dpm/ml for plasma and urine and 14,500 dpm/ml for fecal homogenate) for storage stability monitoring.
Analysis of blood and feces. Triplicate weighed aliquots of each blood sample (0.2 g each) and fecal homogenate (0.3 g each) were combusted and analyzed for radioactivity. The sample combustion was performed in a model 307 sample oxidizer (PerkinElmer Life and Analytical Sciences). The resulting 14 CO 2 was trapped in Carbo-Sorb. Permafluor scintillation cocktail was added, and the radioactivity content was quantitated by liquid scintillation counting (LSC).
Analysis of plasma and urine. Triplicate weighted aliquots of each plasma (0.2 g each) and urine sample (1 g each) were transferred to scintillation vials and analyzed directly for radioactivity. Ultima Gold scintillation cocktail (10 ml) was added to each vial, which was counted in a scintillation counter for 5 min or 100,000 counts. The total plasma/urine radioactivity concentrations were calculated by converting the LSC data (disintegrations per minute) to concentrations (nanogram equivalents per milliliter) using the specific activity (1.378 Ci/mg) of [ 14 C]eltrombopag. Quantitation of eltrombopag in plasma. In addition to quantitation of radioactivity, duplicate aliquots (50 l each) of pharmacokinetic plasma samples were also analyzed for the presence of eltrombopag using a validated HPLC-MS/MS method as described previously (Williams et al., 2009) .
Pharmacokinetic Analysis. Blood and plasma total radioactivity and eltrombopag PK parameters including AUC 0 -t , AUC 0 -ϱ , maximum concentration (C max ), time of C max observed (T max ), and terminal elimination half-life (t 1/2 ) were determined for each subject with noncompartmental analysis using WinNonlin (version 4.1; Pharsight, Mountain View, CA). The ratio of plasma eltrombopag to plasma total radioactivity was calculated to assess the relative amount of radioactivity present as parent compound versus metabolites. The ratio of blood to plasma total radioactivity concentrations at each PK sampling was calculated to assess eltrombopag partitioning into red blood cells. Concentration units for radioactivity are expressed as nanogram equivalents of eltrombopag per milliliter.
Sample Preparation for Metabolite Profiling. Plasma. Each plasma sample collected for metabolite profiling (both nonacidified and acidified) was analyzed individually. Subaliquots of each sample were first analyzed by LSC to confirm radioactivity contents. The samples were then extracted by a series of organic solvents in a procedure modified from ZiaAmirhosseini et al. (1994) . The extraction was initiated by addition of 3 volumes of a mixture of ethyl alcohol and acetonitrile (1:1, v/v) followed by alternate vortex mixing and sonication (15 min each) and centrifugation at 3100g av at 4°C for 5 min. The supernatant was removed to a prelabeled container, and the pellet was extracted once more in the identical procedure. The supernatants from these two cycles of extraction were combined, and triple aliquots were removed for LSC to determine the radioactivity content in the extract. The combined extract was then evaporated under a stream of nitrogen gas to dryness and reconstituted in a freshly prepared mixture of 25 mM ammonium formate, pH 5, and methanol (15%:85%, v/v). The reconstituted extract was vortex-mixed, sonicated, and centrifuged before analysis by radio-HPLC.
Plasma samples (12-, 24-, and 48-h samples) that exhibited less than 90% recovery of radioactivity were further extracted once with 10% aqueous trichloroacetic acid (w/v) and three times with a mixture of methanol and diethyl ether (4:1, v/v). Triplicate aliquots of each extract were assayed for radioactivity content. The pellet was finally solubilized in aqueous sodium hydroxide (1 M) at 50°C overnight and neutralized with an aliquot of glacial acetic acid. Triple subaliquots of each solubilized pellet were analyzed by LSC. The amount of nonextractable radioactivity in the pellet was calculated and expressed as picomoles per milligram of plasma proteins, assuming a healthy adult human plasma protein concentration of 74 mg/g plasma (Guarino et al., 1973) .
To characterize the nature of nonextractable radioactivity, the solubilized pellets of 24-h (combined nonacidified and acidified, subject 6) and 48-h plasma (nonacidified, pooled from six subjects) were extracted once with a mixture of ethyl alcohol and acetonitrile (1:1, v/v). Each extract was then evaporated to dryness and reconstituted in a small volume of a freshly prepared mixture of 25 mM ammonium formate, pH 5, and methanol (15:85%, v/v, for the 24-h plasma pellet) or a mixture of water, formic acid, methanol, and acetonitrile (30:1:35:34%, v/v/v/v, for the 48-h plasma pellet). The reconstituted extract was then centrifuged before radio-HPLC analysis.
Urine. The nonacidified and acidified urine samples from each subject were separately pooled on the basis of the total sample weight collected from each interval to produce a single pooled representative sample for the subject. The sample pooling details are described in Table 1 . Samples that contained less than 2% of the administered dose were not pooled. The pooled urine samples were centrifuged at 4000g av at ambient temperature for 5 min to remove any particulates before radio-HPLC analysis. Triple aliquots of each pooled urine sample were analyzed before and after centrifugation to determine whether any notable loss of radioactivity had occurred upon centrifugation.
Feces. Fecal samples were pooled to generate a representative sample for each subject as described in Table 1 . The pooled samples were extracted three times with a mixture of methanol, acetonitrile, dimethylformamide, water, and 10% aqueous trifluoroacetic acid (29:29:25:12:5%, v/v/v/v/v) . Each extraction involved addition of 5 volumes of the solvent mixture, followed by sonication for 15 min, mixing for 45 min, and centrifugation (at 3100g av , 5 min at ambient temperature). The supernatants were combined, and the total radioactivity was determined by LSC analysis of triple aliquots of the combined supernatant. The fecal extract was analyzed by radio-HPLC. The residual fecal pellets were then solubilized with aqueous sodium hydroxide (1 M) at 50°C overnight. The solubilized pellets were neutralized with acetic acid for LSC.
Quantitative HPLC Analysis. Agilent 1100 LC systems consisted of a model G1312A pump, a model G1330A autosampler, and a ␤-RAM model 2B radiometric detector with a 500-l homogeneous liquid scintillant flow cell. Aliquots (20 -900 l) of samples were injected onto a Luna C18 analytical column (4.6 ϫ 250 mm, 5 ) and eluted at 1 ml/min with solvents A (water containing 0.1% formic acid) and B (acetonitrile containing 0.1% formic acid). The following four-step gradient was used: 0 to 30 min, 10% solvent B in solvent A; 30 to 60 min, 10 to 30% B in A; 60 to 90 min, 30 to 100% B in A; and 90 to 100 min, 100% B. After elution of eltrombopag and its metabolites, the gradient was switched back to 10% B in A, and the column was washed for 10 min before next injection. Urine samples were analyzed with on-line radiodetection, during which the eluent was mixed with Ultima-Flo M scintillant at a mix ratio of 1:3 by volume. The radioactivity data were collected at 0-96 24-48, 48-72, 72-96, 96-120, 120-144 4 0-72 48-72, 72-96, 120-144, 144-168 5 0-72 24-48, 48-72, 72-96, 96-120, 120-144, 144-168 6 0-72 24-48, 96-120 a For other collection periods, no samples were obtained or the sample contained Ͻ2% of the radiodose. a rate of 1 point/s. The percentage of radioactivity in each peak of the metabolic profile was calculated using WinFlow software (version 1.5; LabLogic Inc., Tampa, FL) and is expressed as the percentage of the administered dose recovered in urine (corrected for the centrifugation recovery). For plasma and fecal extracts that contained a radioactivity level that was too low for radiometric flow detection, the HPLC eluent was collected onto four 96-well solid scintillant LUMA microtiter plates (PerkinElmer Life and Analytical Sciences) at 0.258 min/well. The solvents in the microtiter plates were evaporated at approximately 40°C to dryness in an oven. The dried plates were then heat-sealed using TopSeal-S film (PerkinElmer Life and Analytical Sciences) FIG . 2. Mean concentration-time profiles of plasma eltrombopag and metabolites M1 and M2, and blood and plasma total radiocarbon. and analyzed using a Packard TopCount scintillation counter. Each well was counted for 5 min without background subtraction. The resulting TopCount data were imported into the WinFlow software using its "LSC Import" function and processed by Microsoft Excel 2002 to reconstruct radio-HPLC chromatograms. Each radioactive peak was calculated as a percentage of the total counts detected and is expressed as nanogram equivalents of eltrombopag per gram of plasma (corrected for the overall recovery of extraction and reconstitution) or the percentage of the dose recovered in feces (corrected for the combustion and extraction recovery). The lower limit of quantification was defined as one time (fecal samples) or three times (plasma and urine) the background area integrated in each chromatogram. Mass Spectroscopic Analysis. Metabolite characterization was conducted by one or more of the following: LC-MS/MS, LC-multiple reaction monitoring, and LC-MS accurate mass analysis. The LC conditions were similar to those used for metabolite profiling as described above. The HPLC eluent was split at a 1:9 ratio between a mass spectrometer and a radiometric flow detector. Nominal mass measurements and MS/MS experiments were performed on a Thermo Fisher Scientific LTQ mass spectrometer equipped with an ESI source (Thermo Fisher Scientific, Waltham, MA). Accurate mass measurements were performed on a Waters QToF II instrument equipped with an ESI source (Waters, Milford, MA). LC-multiple reaction monitoring measurements were performed on a Waters Ultima Triple Quadrupole instrument equipped with an ESI source. All instruments used a CTC PAL autosampler for sample introduction. Data were acquired and processed using Xcalibur software (version 1.4; Thermo Fisher Scientific) or MassLynx software (version 3.5; Waters).
High-Field NMR Analysis. All spectra were obtained on a Bruker Avance DRX 700-MHz NMR spectrometer Bruker (Newark, DE) equipped with a 2.5-mm BBI probe or a 5-mm TCI cryoprobe or on a Varian Inova 600-MHz NMR spectrometer (Varian, Inc., Palo Alto, CA) equipped with a 3-mm HFC gradient probe. 1 H and 13 C NMR chemical shifts were referenced to the residual solvent signals of dimethyl sulfoxide (2.49 and 39.5 ppm) or methanol (3.30 and 49.0 ppm), as appropriate. All NMR experiments conducted used pulse sequences coded in the standard Bruker or Varian software.
Metabolite Isolation. M1 was isolated from an in vitro incubation with human liver microsomes, whereas M2 was isolated from bile of isolated perfused rabbit livers. M3, M4, and M6 were isolated from human excreta, and M5 was isolated from rat bile. Details of metabolite generation and/or isolation are presented as supplemental data.
Results
Mass Balance of Radioactivity. Six healthy male volunteers with a mean age of 36 years received a single 75-mg oral dose of [
14 C]eltrombopag olamine (102 Ci). The drug was well tolerated with no adverse events observed. The excretion of total radioactivity in urine and feces is summarized in Table 2 . By 168 h postdose, 59% (41-70%) of the administered radioactivity was excreted in feces. The corresponding radiodose recovered in the urine averaged 31% (23-45%), the majority of which was achieved within 48 h postdose (mean recovery of 23%). The total recovery of radioactivity was 90% (84 -93%).
Eltrombopag and Total Radioactivity Pharmacokinetics. Median concentration-time profiles for blood and plasma radioactivity and plasma eltrombopag are displayed in Fig. 2 . Blood concentrations of total radioactivity were 51 to 67% of plasma radioactivity concentrations at corresponding time points. The mean percentage of radioactivity associated with red blood cells ranged from 0 to 16%, indicative of minimal association of eltrombopag or its metabolites with red blood cells. Eltrombopag concentrations were detectable in plasma at the first sampling time point (0.5 h after dosing). For the first 12 h postdose, the plasma concentration of total radioactivity was similar to that of eltrombopag, suggesting that the unchanged drug predominated in circulation (Fig. 2) . The total radioactivity concentration started to exceed that of eltrombopag after 12 h, indicating that circulating metabolite concentrations were increasing relative to that of the parent.
A summary of blood and plasma total radioactivity and plasma eltrombopag pharmacokinetic parameters is presented in Table 3 . Individual ratios of plasma eltrombopag versus plasma total radioactivity AUC 0 -ϱ ranged from 53 to 71%, with an average ratio of 60%. The t 1/2 of total plasma radioactivity was longer than that of eltrombopag (49.3 and 32.3 h, respectively).
Extractability and Metabolite Profiles in Plasma. The majority of plasma radioactivity was recoverable through solvent extraction (94, 95, 89, and 85 at 4, 12, 24 , and 48 h postdose, respectively). Subsequent solubilization of the plasma protein pellets yielded an additional 12, 16, and 20% for 12-, 24-, and 48-h samples, respectively (4-h samples were not exhaustively extracted because of Ͼ90% recovery after the initial extraction as described under Materials and Methods). Nonextractable eltrombopag-related materials corresponded to 14, 13, and 10 pmol/mg plasma protein at 12, 24, and 48 h postdose, respectively).
The relative amounts of eltrombopag and quantifiable metabolites in plasma after oral administration of [ 14 C]eltrombopag are shown in Table 4 , and median concentration-time profiles for plasma eltrombopag and quantifiable metabolites are displayed in Fig. 2 . Representative HPLC radiochromatograms of plasma are depicted in Fig. 3 . Acidification did not have an impact on the plasma radioprofiles (data not shown). Unchanged eltrombopag was the predominant circulating component at all sample times, accounting for Ͼ62% of total plasma N.A., not available because the metabolite was quantifiable in one or two of six subjects only as described above; N.Q., below level of quantitation.
a M1 was quantifiable only in subject 1 at 4 h (2.4%) and subject 6 at 12 h (5.0%) and not quantifiable in other subjects.
b M2 was a mixture of three coeluting acyl glucuronide isomers; this metabolite was quantifiable only in subject 3 (3.7%) at 4 h and in subject 1 (11%) and subject 4 (2.8%) at 12 h and was not quantifiable in other subjects at these two sampling points. Metabolite M1, a product of mono-oxygenation of eltrombopag, was a minor component, accounting for Ͻ1% of total radioactivity at all time points studied. Metabolite M2, which was composed of three coeluting acyl glucuronide isomers of eltrombopag, accounted for less than 1% at 4 h and approximately 12% of plasma radioactivity at 48 h postdose. Alkaline digestion of the residual plasma protein pellets produced after solvent extraction of the samples released additional radioactivity. This additional radioactivity was characterized by LC-MS analyses as eltrombopag and metabolite M1 (Fig. 4) .
Metabolite Profiles in Urine.
A representative HPLC radiochromatogram of urine after oral administration of [ 14 C]eltrombopag is depicted in Fig. 5 . The individual and mean quantification of metabolites from the six subjects are shown in Table 5 . The metabolite profiles were similar across the six subjects, with metabolite M4, the glucuronide of a hydrazine cleavage product of eltrombopag, as the major radiocomponent. Further analysis of urine samples using NMR detected the nonlabeled portion of the hydrazine cleavage pathway (the biphenyl moiety). The metabolite was a glucuronide conjugate FIG. 3 . HPLC radiochromatograms of acidified human plasma after oral administration of [ 14 C]eltrombopag (75 mg, 100 Ci). Plasma from the six human subjects was analyzed individually by solvent extraction followed by LC-MS analysis with radiometric detection. Top, subject 6, 4 h. Middle, subject 6, 24 h. Bottom, subject 6, 48 h. P, [ dmd.aspetjournals.org (M3) and quantification using NMR revealed it to be present in urine at a concentration similar to that of M4. An additional radiolabeled metabolite was detected in the urine from subject 3. This metabolite (unknown 1) was not structurally characterized and accounted for approximately 5% of the administered dose. Neither eltrombopag nor any of the characterized circulating metabolites were observed in urine. Acidification did not alter the urinary radioprofiles (data not shown).
Metabolite Profiles in Feces. The majority of the radioactivity present in feces (Ն81%) was extractable by organic solvents. Solubilization of the fecal pellets after extraction recovered another 18% of radioactivity. A representative HPLC radiochromatogram of eltrombopag-related materials in fecal extracts is shown in Fig. 6 . The individual and mean percentages of eltrombopag and metabolites excreted in feces are presented in Table 5 . Both qualitative and quantitative differences in fecal radioprofiles were evident for the six subjects. Unchanged eltrombopag was the major radiocomponent in the feces, accounting for approximately 20% of the dose. Three coeluting glutathione-related conjugates of eltrombopag (M5, glutathione; M6, cysteine; and M7, glutamyl cysteine) were also prominent, together accounting for another 21% of the dose. Although the fecal eltrombopag levels were comparable in all subjects (15-26% of dose), the abundance of the glutathione-related conjugates (metabolites M5, M6, and M7) notably differed, ranging from 4 to 37% of the administered dose. A radiocomponent with unknown identity (unknown 2) was also observed in three subjects, accounting for 6 to 9% of the administered dose. None of the circulating metabolites or urinary metabolites was observed in feces.
Structural Characterization of Metabolites. Metabolite structures were elucidated by LC-MS and NMR analysis. Summaries of 1 H NMR and 13 C NMR data, and the HPLC retention times and MS/MS data are depicted in Tables 6, 7 , and 8, respectively. The NMR numbering schemes for eltrombopag and its metabolites are depicted in Fig. 7 . In general, LC-MS data (both full scan and MS n ) provided a Markush structure for the metabolites. Definitive structures were subsequently determined by NMR analysis of the metabolites isolated from various biological samples. Where possible, relevant standards were also analyzed in parallel to assist in the metabolite identification.
Metabolite M1. The HPLC retention time of M1 was 79.2 min. The pseudo-molecular ion at m/z 459 was 16 Da higher than that of eltrombopag, indicating mono-oxygenation. The fragmentation ions at m/z 229, 228, 211, 210, and 184 are coincident with those observed in the MS/MS spectrum of eltrombopag. These ions are all derived from the biphenyl portion of eltrombopag, thereby isolating the site of biotransformation to the phenylpyrazole moiety. Furthermore, the disappearance of one of the aromatic methyl 1 H NMR signals in conjunction with the appearance of a new signal at 4.49 ppm indicates that one of the aromatic methyl moieties has been substituted with an oxygen. Double pulsed field gradient rotating Overhauser effect spectroscopy; data reveal that this new 1 H signal at 4.49 ppm is proximal to an aromatic proton at 7.40 ppm, H23, thereby establishing methyl 28 as the site of biotransformation.
Metabolite M2. The HPLC retention time of M2 was 82.4 min. The pseudo-molecular ion at m/z 619 was 176 Da higher than that of eltrombopag, indicating glucuronidation. The fragmentation ion at m/z 443 (loss of 176 Da) supports this hypothesis. NMR spectroscopy confirmed the presence of an O-substituted glucuronide with the anomeric proton at 5.57 ppm and carbon at 94.9 ppm. These chemical shifts are consistent with an acyl glucuronide as opposed to an ether linkage for the glucuronide. gHMBC data yielded a coupling between the anomeric proton and a carbon at 164.9 ppm, thereby confirming that M2 was an acyl glucuronide of eltrombopag.
Metabolite M3. M3 was discovered in a 1 H NMR screen of a preparative HPLC separation of human urine. The HPLC retention time of M3 was 55.9 min.
1 H NMR revealed two aromatic spin systems corresponding to the biphenyl moiety of eltrombopag. An additional proton spin system consistent with a glucuronide was observed with the anomeric proton and carbon at 4.25 and 105.4 ppm, respectively. The anomeric carbon chemical shift is diagnostic for an FIG. 6 . HPLC radiochromatogram of extract from a pooled human feces sample after oral administration of [ 14 C]eltrombopag (75 mg, 100 Ci). Pooled fecal samples from each of the six human subjects were individually analyzed by solvent extraction followed by LC-MS analysis with radiometric detection. ether glucuronide. A correlation from the gHMBC experiment between the glucuronide anomeric proton and a carbon at 145.7 ppm indicated that the glucuronide was conjugated through the phenolic oxygen. M3 was subsequently characterized by accurate mass LC-MS (observed mass ϭ 448.1226 Da, C 21 H 22 NO 10 , Ϫ4.0 ppm error). The fragmentation ion at m/z 272 (loss of 176 Da) was also consistent with the presence of a glucuronide. Metabolite M4. The HPLC retention time of M4 was 41.9 min. The pseudo-molecular ion at m/z 394 suggested that M4 could be a cleavage product of eltrombopag. The fragmentation ion at m/z 218 (loss of 176 Da) indicated that M4 was a glucuronide conjugate.
1 H NMR data indicated that a 1,3,4-trisubstituted aromatic spin system was present in addition to three methyl singlets. These data were consistent with the phenylpyrazole portion of eltrombopag being the structural core of M4. An additional proton spin system consistent with a glucuronide was observed with the anomeric proton and carbon at 4.72 and 104.9 ppm, respectively. The anomeric carbon chemical shift is diagnostic for an ether glucuronide.
Metabolite M5. The HPLC retention time for M5 was 70.8 min. The pseudo-molecular ion at m/z 748 was 305 Da higher than eltrombopag, indicating possible glutathionyl conjugation. The fragmentation ions at m/z 673, 619, and 441 indicated the losses of the glycinyl, glutamyl, and glutathionyl moieties, respectively. The combination of gradient nuclear Overhauser effect spectroscopy data (aromatic proton at 7.31 ppm, H23, was proximal to a signal at 3.76 ppm, H28) and gHMBC data (aromatic proton at 7.74 ppm, H26, correlates to C27 at 18.5 ppm; aromatic proton at 7.31 ppm, H23, correlates to C28 at 32.7 ppm; and aromatic methyl at 2.37 ppm, H27, correlates to carbons at 132.2, 137.2, and 119.1 ppm corresponding to C24, C25, and C26, respectively) confirmed the site of glutathionyl conjugation as methyl 28.
Metabolite M6. The HPLC retention time for M6 was 70.7 min. The pseudo-molecular ion at m/z 562 was 119 Da higher than eltrombopag, and this was consistent with a cysteine conjugate. The disappearance of one of the aromatic methyl 1 H NMR signals in conjunction with the appearance of a new signal at 3.87 ppm indicates that one of the aromatic methyl moieties has been substituted. gHMBC data revealed a coupling between one of the remaining aromatic methyl groups, H27, and C26, thereby implicating C28 as the site of biotransformation. Furthermore, an additional spin system was observed whose proton and carbon chemical shifts were consistent with the presence of a cysteinyl moiety. The fragmentation ion at m/z 562 indicates the loss of the glutamyl moiety whereby the ion at m/z 441 represents the loss of the entire cysteinyl glutamyl moiety. No fragmentation ions were observed that could be used to elucidate the exact site of biotransformation. However, both metabolites M6 and M7 could be derived from degradation of metabolite M5. Biodegradation of a glutathione conjugate to corresponding glutamyl cysteine and/or cysteine conjugates has been demonstrated (Schneider et al., 1998; Frankmoelle et al., 2000) .
Discussion
This study evaluated the pharmacokinetics, metabolism, and excretion of [ 14 C]eltrombopag after a single oral solution dose of 75 mg to six healthy male volunteers. The exposure from the solution was approximately twice that of the 75-mg tablet formulation (Williams et al., 2009) . Eltrombopag was also absorbed with a median T max of 2.5 h, shorter than the 4 h reported after a single tablet administration. The plasma eltrombopag t 1/2 (32.3 h) was longer than reported previously for eltrombopag (16.7 h) (Williams et al., 2009 ) probably because of the longer duration of PK sampling (out to 7 days versus 2 days postdose). After oral administration, urinary elimination of radioactivity occurred within 12 h postdose (first urine sampling), peaking on the 2nd day (24 -48 h) and was essentially complete within 3 days (86% of the total dose eliminated in urine was recovered during this period) (Table 2) . However, fecal elimination of radioactivity was much slower, with radioactivity still detectable in the feces of the last collection interval on day 7.
The plasma half-life of eltrombopag (32 h) was shorter than that of circulating radioactivity (49 h), indicating that the circulating metabolites might persist longer than the parent drug. Two minor dmd.aspetjournals.org metabolites [a hydroxylated metabolite (M1) and three coeluting acyl glucuronide isomers (M2)] were circulating. However, these metabolites (sampled up to 48 h postdose only) were present at relatively low concentrations (Fig. 2) and, therefore, did not account for the difference between parent and total radioactivity exposure or the prolonged radioactivity half-life. Nonextractable, radioactivity covalently bound to plasma proteins may have contributed to the higher plasma exposure and longer half-life of total radioactivity.
Absorbed eltrombopag was extensively metabolized. The metabolic scheme of eltrombopag in humans is presented in Fig. 1 dmd.aspetjournals.org oxygenation of the para-methyl group of the phenylpyrazole moiety to form M1, acyl glucuronidation to form M2, and cleavage of the hydrazine linkage, which combined with secondary conjugation pathways to produce M3 and M4. M1 can undergo further biotransformation, followed by conjugation with glutathione, resulting in the formation of M5, M6, and M7, although these metabolites could be formed via an intermediate discrete from M1 (Fig. 1) . The metabolites derived from mono-oxygenation (M1) and acyl glucuronidation (M2) of eltrombopag were detected only in plasma, the hydrazine cleavage products (M3 and M4) were eliminated in the urine, and the glutathione-related conjugates (M5, M6, and M7) were detected only in the feces. The absence of M1 and M2 in human feces could result from their secondary metabolism or reactivity (as illustrated in Fig. 8 ) and/or biliary or gut instability (M2). As a result, the contribution of these two primary pathways to the overall metabolism and disposition of eltrombopag in humans could not be accurately estimated. The urinary metabolites (cleavage products of eltrombopag) were not observed in human plasma. Eltrombopag is cleaved by gut microbes (Deng et al., 2011 ). The cleavage products are then quickly absorbed, metabolized, and eliminated in urine. As demonstrated in mice with one in vitro cleavage product of eltrombopag, SB-611855, the plasma concentrations of this cleavage product reached a maximum within 5 min after oral administration of SB-611855 but decreased below the limit of quantitation within 3 h postdose (Deng et al., 2011) . This rapid rate of elimination might explain the absence of cleavage products in circulation in metabolism studies in which metabolite sampling typically started from 4 h postdose. Variations in gut microbial activity could have contributed to the marked difference in urinary elimination of eltrombopag-related materials observed in humans. After oral administration of [ 14 C]eltrombopag, the extent of urinary elimination ranged from 23% in subjects 1 and 5 to 45% in subject 2.
The identification of glutathione-related conjugates, acyl glucuronides, and the low levels of nonextractable drug-related material in plasma suggests the potential for the formation of reactive metabolites. A para-imine methide, probably derived from the secondary oxidative metabolism of M1 is a proposed metabolic intermediate (Fig. 8) . The formation of methides has been reported as a bioactivation pathway for a number of drugs, although quinone methides are more typically involved (Bolton et al., 1990; Fan and Bolton, 2001; Kassahun et al., 2001; Zhang et al., 2003; Yan et al., 2005 ). An imine methide intermediate has been proposed as one of the bioactivation pathways for diclofenac (Grillo et al., 2008) and for 3-methylindole (Nocerini et al., 1985) . The imine methide of eltrombopag could react with nucleophilic amino acid residues to become covalently bound protein adducts or be detoxified by reacting with glutathione to form M5 or water to regenerate M1. As presented in Fig. 8 , alkaline digestion of human plasma protein pellets released M1, resulting from hydrolysis of the covalently bound eltrombopag metabolite that had formed through a putative methide intermediate. Acyl glucuronides have also been implicated as reactive intermediates in the covalent binding to proteins. Zia-Amirhosseini et al. (1994) proposed that covalent binding of tolmetin to human proteins was through an acyl glucuronide, which reacted with proteins either via a nucleophilic displacement or a Schiff base intermediate. Acyl glucuronide-mediated covalent binding has also been reported for valproic acid and zomepirac (Takakusa et al., 2008) . In this study, alkaline digestion of human plasma protein pellets released eltrombopag in addition to M1 (Fig. 8) , consistent with the speculation that acyl glucuronides of eltrombopag might covalently bind to plasma proteins as well.
The clinical relevance of low levels of covalent binding of eltrombopag-related material to plasma proteins is unknown. Covalent binding to biological macromolecules has been observed with drugs that are generally considered as safe (e.g., captopril and aspirin), drugs associated with hepatotoxicity (e.g., acetaminophen overdose), and drugs associated with idiosyncratic reactions (e.g., diflunisal and zomepirac) (Uetrecht, 1992; Pumford and Halmes, 1997; Evans et al., 2004; Walgren et al., 2005; Zhou et al., 2005) . However, the role of covalent binding in hepatotoxicity and idiosyncratic reactions has not been conclusively established, and covalent binding alone may not be sufficient to cause these events, as Uetrecht (2003) describes in the danger or pharmacological interaction hypotheses. The levels of potentially covalently bound eltrombopag-related material in plasma were 14 pmol/mg protein in human and 4, 3, and 5 pmol/mg protein in the mouse, rat, and dog, respectively (reported in the supplemental data). Of importance, these peak values, typically observed at the initial sampling time, decreased over the remainder of the sampling period. In rats administered 10 mg/kg [ 14 C]eltrombopag, the amount of potentially covalently bound material in the liver was 69 pmol/mg liver protein at 4 h. This peak level was comparable to a conservative in vitro or in vivo target covalent binding level recommended for drug candidates (50 pmol/mg liver protein) by Evans et al. (2004) but well below the observed covalent binding level produced by prototypic hepatotoxins (1000 pmol/mg liver protein). The levels decreased to 8 pmol/mg liver protein by 48 h. In the mouse (10 mg/kg), at the early sample times extractability was greater than 90%, and, therefore, further evaluations were not conducted. At the 24-and 48-h sampling times, where extractability was less than 90%, the level of potentially covalently bound material was less than 2 pmol/mg liver protein.
In conclusion, after a single oral solution dose, eltrombopag was quickly absorbed. Unchanged parent was the predominant circulating component. Products derived from mono-oxygenation and acyl glucuronidation of eltrombopag also circulated, albeit in small quantities. The drug-related material covalently bound to plasma proteins and could have contributed to the persistent plasma radioactivity. Eltrombopag was extensively metabolized by mono-oxygenation, glucuronidation, hydrazine cleavage, and secondary oxidation and conjugation. Overall, drug-related material was eliminated in feces and urine at a ratio of 2:1 over the 7 days after dosing. The hydrazine cleavage metabolites, probably the products of gut microbial reductive biotransformation, were eliminated in urine exclusively. Glutathione conjugates, detected in feces only, were probably detoxification products of a potentially reactive metabolite (a p-imine methide). The oxidation and glucuronidation products of eltrombopag were not observed in excreta probably because of their secondary metabolism and/or instability during elimination.
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Supplemental Data Introduction
Several preclinical studies were conducted to characterize covalent binding in animals. These studies were briefly described as follows. In addition, metabolite isolation procedures, including those from human excreta, were also described in this section. 
Materials and Methods
Collection of Animal Samples for
